Aegis reaffirmed their buy rating on shares of CytRx Corporation (NASDAQ:CYTR) in a report released on Monday. CytRx (NASDAQ:CYTR) last issued its quarterly earnings data on Thursday, May 1st. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.27. On average, analysts predict that CytRx will post $-0.47 earnings per share for the current fiscal year. CytRx Corporation (NASDAQ:CYTR) stock opened today at $4.13 and is currently trading at $4.39. The stock showed a positive weekly performance of 4.79%.
MannKind Corporation (NASDAQ:MNKD) will present at upcoming conferences: Goldman Sachs 35th Annual Global Healthcare Conference on June 12, 2014 at 11:20 am (PT) at the Terranea Resortin Rancho Palos Verdes, California. MannKind Corporation (NASDAQ:MNKD) stock opened at $9.71, in current trading session and currently is at $9.91, by gaining 4.21%. The 52 week range of $9.70 – $10.05. Company’s market capitalization is $3.85 billion.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) stock is currently trading at $11.78. The EPS of the stock is -1.30. Company’s market capitalization is $399.00 million.
On May 22, Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced that the U.S. Food and Drug Administration (FDA) has extended the initial Prescription Drug User Fee Act (PDUFA) goal date for its review of the Company’s New Drug Application (NDA) seeking marketing approval of ZerenexTM (ferric citrate) by three months. The new PDUFA goal date is September 7, 2014. Keryx Biopharmaceuticals (NASDAQ:KERX) stock opened the session at $ 13.20, and now is at $13.72. The 52 week range of the stock remained $6.61 – $17.46 and the day range was $13.14 – $13.76.
Omeros Corporation’s (NASDAQ:OMER) Omidria 1%/0.3% has been approved by the U.S. Food and Drug Administration (FDA) for reducing postoperative pain during cataract surgery or intraocular lens replacement (ILR) and maintaining pupil size by preventing intraoperative miosis (pupil constriction). Omeros Corporation (NASDAQ:OMER) stock opened today at $11.43 and is currently trading at $11.42. The stock showed a negative weekly performance of -2.89%.
Leave a Reply